Fig. 6: Implanted ePOWER therapy in rats with MI.
From: Programmable production of bioactive extracellular vesicles in vivo to treat myocardial infarction
a Schematic of the study design. After successful MI modeling, ePOWER was surgically implanted and treated accordingly. Echocardiography was performed 4 weeks after treatment. b Representative M-mode echocardiography images in each group after 4 weeks. c Quantification of LVEF percentage after 4 weeks of treatments (n = 5). d Representative MASSON staining of heart tissues in different groups (scale bar, 1 mm). e Quantification of the size of infarct areas after different treatments (n = 5). f Representative angiogenesis staining of the infarct boundary area in different groups. Immunostained with anti-CD31 antibodies (blue: DAPI, red: CD31, scale bars, 100 μm). g Quantification of the number of angiogenesis in the infarct boundary area in different groups (n = 3). Statistical differences were analyzed using one-way ANOVA with a Tukey multiple comparisons test. The data was represented by an average of ± SD.
